CAJ | 학술논문

目的：探讨舒利迭（50/500）联合不同剂量的辛伐他汀治疗慢性阻塞性肺疾病（COPD）的疗效。方法将2011年6月-2012年6月在宜春市第二人民医院确诊的COPD急性加重期住院患者250例随机分为五组，按需吸入沙丁胺醇组为对照组，规律吸入舒利迭组为舒利迭组，根据舒利迭联合辛伐他汀剂量的不同，分为辛伐他汀10 mg、20 mg、40 mg联合组，每组各50人。治疗6个月后，比较各组再次急性加重的人数、死亡人数。结果各组急性加重的次数及死亡人数分别为[（19、9、8、5、3），(χ2=21.07,P<0.05)]和[（8、4、3、2、1），(χ2=11.05,P<0.05)]。结论舒利迭联合辛伐他汀治疗COPD，在降低急性发作频率及死亡率方面与对照组及舒利迭单药组相比，有明显优势，而且随着辛伐他汀剂量的增加而增大。
목적：탐토서리질（50/500）연합불동제량적신벌타정치료만성조새성폐질병（COPD）적료효。방법장2011년6월-2012년6월재의춘시제이인민의원학진적COPD급성가중기주원환자250례수궤분위오조，안수흡입사정알순조위대조조，규률흡입서리질조위서리질조，근거서리질연합신벌타정제량적불동，분위신벌타정10 mg、20 mg、40 mg연합조，매조각50인。치료6개월후，비교각조재차급성가중적인수、사망인수。결과각조급성가중적차수급사망인수분별위[（19、9、8、5、3），(χ2=21.07,P<0.05)]화[（8、4、3、2、1），(χ2=11.05,P<0.05)]。결론서리질연합신벌타정치료COPD，재강저급성발작빈솔급사망솔방면여대조조급서리질단약조상비，유명현우세，이차수착신벌타정제량적증가이증대。
Objective To evaluate the efficacy of Seretide (50/500) combined with different doses of simvastatin treating chronic obstructive pulmonary disease (COPD). Methods A total of 250 patients who were diagnosed acute exacerbation chronic obstructive pulmonary disease (AECOPD) in the hospital from June 2011 to June 2012 were collected, and were randomly divided into five groups:the control group、the Seretide group、the simvastatin 10 mg、20 mg、40 mg combination group, respectively. Each group had twenty cases. There were 45 cases of group A、83 cases of group B、34 cases of group C、88 cases of group D, included 131 cases of male with a mean age of (67 ± 14) years and 119 cases of female with a mean age of (65 ± 16) years. The frequency of acute exacerbation and mortality were compared to after treatment for six months. Results The numbers of each group of acute exacerbation and death were [(19、9、8、5、3);(χ2=21.07,P<0.05)] and [(8、4、3、2、1);(χ2=11.05,P<0.05)] after six months.Conclusion Compared to the control group and the seretide group treating COPD ,the simvastatin combination group could reduce the frequency of acute exacerbation and mortality,With the doses of the simvastatin increasing,these quotas could be improved more significantly.